Comparison of efficacy of mirabegron and darifenacin in overactive bladder- a prospective study

Authors

  • Gurpreet Singh Bhangu Department of Surgery, SGRD University, Amritsar, Punjab, India
  • Kamal Preet Kaur Department of Surgery, SGRD University, Amritsar, Punjab, India
  • Darpan Bansal Department of Surgery, SGRD University, Amritsar, Punjab, India
  • Ritansh Bansal Department of Surgery, SGRD University, Amritsar, Punjab, India

DOI:

https://doi.org/10.18203/2349-2902.isj20205665

Keywords:

Overactive Bladder, Darifenacin, Mirabegron

Abstract

Background: Overactive bladder (OAB) is under reported yet distressing symptoms which can be managed effectively by the drugs available. Aim was to study and compare the efficacy of two drugs, mirabegron and darifenacin in controlling the symptoms of overactive bladder.

Methods: This prospective study included a total of 120 cases of overactive bladder reported at Sri Guru Ram Das Institute of Medical Sciences and Research, Amritsar from January 2018 to December 2019. This comparative study was done by giving Mirabegron to first five patients and next five patients were given darifenacin up to 120 patients. The drug treatment with once daily administration of 25 mg mirabegron and 7.5 mg of darifenacin was given for a total of 12 weeks. The signs and symptoms were noted at the beginning of the therapy and then follow up was done at 4, 8, 10 and 12 weeks.

Results: Total 54 out of 60 patients (90%) on miragaberon and 59 of 60 patients (98.33%) on darifenacin were relieved of symptom of increased frequency of micturition. 53 of 60 pateints (88.33%) on miragaberon and 59 of 60 patients (98.33%) on darifenacin were relieved of symptom of decreased average voiding volume. 28 of 60 pateints (46.67 %) on miragaberon showed nocturia as compared to 25 of 60 patients (41.67%) on darifenacin.

Conclusions: It has been concluded that both mirabegron as well as darifenacin are highly efficacious newer treatment options for the management of OAB. Our study found Darifenacin to be relatively more efficacious in the treatment of OAB at a lesser dose and statistically significant differences were observed between the two drugs.

 

Author Biographies

Gurpreet Singh Bhangu, Department of Surgery, SGRD University, Amritsar, Punjab, India

Department of Surgery , Associate Professor

Kamal Preet Kaur, Department of Surgery, SGRD University, Amritsar, Punjab, India

Department of surgery , PG resident

Darpan Bansal, Department of Surgery, SGRD University, Amritsar, Punjab, India

Department of Surgery , Associate Professor

Ritansh Bansal, Department of Surgery, SGRD University, Amritsar, Punjab, India

Department of Surgery, PG reident

References

Nitti VW. Clinical Impact of Overactive Bladder. Rev Urol. 2002;4(Suppl 4):S2–6.

Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49.

Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14.

Scheife R, Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther. 2005;27(2):144–53.

Sexton CC, Coyne KS, Thompson C, Bavendam T, Chen C-I, Markland A. Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc. 2011;59(8):1465–70.

Lee UJ, Scott VCS, Rashid R, Behniwal A, Wein AJ, Maliski SL, et al. Defining and managing overactive bladder: disagreement among the experts. Urology. 2013;81(2):257–62.

Willis-Gray MG, Dieter AA, Geller EJ. Evaluation and management of overactive bladder: strategies for optimizing care. Res Rep Urol. 2016;8:113–22.

Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016;7(5):204–16.

Haab F. Darifenacin in the treatment of overactive bladder. Drugs Tod Barc Spain 1998. 2005;41(7):441–52.

Zinner N, Kobashi KC, Ebinger U, Viegas A, Egermark M, Quebe-Fehling E, et al. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract. 2008;62(11):1664–74.

Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95.

12. Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proc Bayl Univ Med Cent. 2007 Jul;20(3):307–14.

13. Coyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int. 2003 Dec;92(9):948–54.

Andersson K-E, Van Kerrebroeck P. Pharmacotherapy for Nocturia. Curr Urol Rep. 2018;19(1).

Salazar A, Svicarovic I, Iglesias T, Orellana S, Salazar I. Evaluation of therapeutic effect of darifenacin in patients with overactive bladder using bladder diary in responders. Informat Communicat Soc. 2014.

Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104(3):352–60.

Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, et al. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Heal Qual Life Outcom. 2018.

Downloads

Published

2020-12-28

Issue

Section

Original Research Articles